MedImmune, LLC
319 North Bernardo Avenue
Mountain View
California
94043
United States
Tel: 650-919-6598
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
Last Updated: 07-10-2008
65 articles about MedImmune, LLC
-
Micromet Buys Out MedImmune, LLC's Remaining Rights to Blinatumomab
11/5/2009
-
Fourteen Abstracts Featuring MedImmune, Inc.'s Influenza and RSV Therapeutic Areas to Be Presented
4/29/2008
-
Desperate But Not Crazy
12/20/2007
-
MedImmune, Inc. Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11/26/2007
-
AstraZeneca PLC Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Group PLC Into MedImmune, Inc.
10/29/2007
-
MedImmune, Inc. Founder, Wayne T. Hockmeyer, Ph.D., Retires
6/19/2007
-
MedImmune, Inc. Announces Make-Whole Fundamental Change Relating to its 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013
6/19/2007
-
MedImmune, Inc. is Awarded Contract by U.S. Department of Health and Human Services to Retrofit Manufacturing Facilities for Production of Pandemic Influenza Vaccines
6/15/2007
-
MedImmune, Inc. Wins Stevie(R) Award at 5th Annual American Business Awards(SM)
6/12/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Present Updated Phase I Results of IPI-504 in GIST at American Society of Clinical Oncology Annual Meeting
6/5/2007
-
Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Updated Data On IPI-504 to be Presented At American Society of Clinical Oncology
5/31/2007
-
US FDA Faults MedImmune, Inc. Over Contamination Issues; FluMist Approval Delayed
5/29/2007
-
MedImmune, Inc. Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
5/24/2007
-
FDA Advisory Committee Recommends Expanded Use of MedImmune, Inc.'s (Jobs) FluMist(R)
5/17/2007
-
FDA Says MedImmune, Inc. Flu Vaccine Works in Children Under Age 5, but Raises Some Safety Concerns
5/14/2007
-
MedImmune, Inc. Data Show FluMist(R) May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings
5/9/2007
-
MedImmune, Inc. Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5/8/2007
-
MedImmune, Inc. Provides Fellowship Grants To Six Pediatric Respiratory Researchers
5/7/2007
-
MedImmune, Inc. and Pediatric Infectious Diseases Society Present 2007 Career Development Award and Viral Respiratory Disease Fellowship
5/7/2007
-
MedImmune, Inc. Announces Convertibility of 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013
5/3/2007